Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Poised For Near-Term Consolidation Despite WMDST Valuation Under-Valued
![]() |
Crinetics enters a phase of reduced momentum after a string of corporate filings and regulatory news, while fundamentals show heavy R&D spending, strong liquidity, and a WMDST valuation that rates the stock under-valued. |









